Register

Support: 888-992-3836|NewsWire|Home|Login / Register

Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Thanks Clay. Now we go down 5% tomorrow.

Public Reply | Private Reply | Keep | Last Read

Next 10 | Previous | Next

MARINO

Followed By	148
Posts	15,397
Boards Moderated	0
Alias Born	10/25/06

160x600 placeholder

Amarin Q4 results led by strong Vascepa sales Seeking Alpha - 2/25/2021 9:48:43 AM

Current Report Filing (8-k) Edgar (US Regulatory) - 2/25/2021 6:07:01 AM

Amarin EPS beats by $0.04, beats on revenue Seeking Alpha - 2/25/2021 5:58:27 AM

Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire Inc. - 2/25/2021 5:55:00 AM

Amarin Q4 2020 Earnings Preview Seeking Alpha - 2/24/2021 11:55:46 AM

Nextech AR (OTCQB: NEXCF) $13 million Deal, Guidance to $50-60 Million, $8.60 Valuation InvestorsHub NewsWire - 2/22/2021 6:18:20 AM

Amarin to Present at Two Upcoming Investor Conferences GlobeNewswire Inc. - 2/18/2021 6:05:00 AM

Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021 GlobeNewswire Inc. - 2/17/2021 8:05:00 AM

Nextech AR (OTCQB: NEXCF) 2021 Guidance $50-60 Million Closes 2020 with $20 million. InvestorsHub NewsWire - 2/12/2021 6:26:34 AM

Amarin Provides Update on VASCEPA® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong GlobeNewswire Inc. - 2/9/2021 7:00:00 AM

Current Report Filing (8-k) Edgar (US Regulatory) - 1/29/2021 5:01:28 PM

Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction GlobeNewswire Inc. - 1/29/2021 12:51:51 PM

VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Re... PR Newswire (Canada) - 1/28/2021 6:30:00 AM

Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider GlobeNewswire Inc. - 1/25/2021 7:35:00 PM

Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascul... GlobeNewswire Inc. - 1/21/2021 4:30:00 PM

The FDA Calendar Review Dates Can Play a Big Role in Timing Your Trades, But Not the Way You May Think InvestorsHub NewsWire - 1/7/2021 8:00:00 AM

Current Report Filing (8-k) Edgar (US Regulatory) - 1/7/2021 6:16:40 AM

Amarin Provides Preliminary 2020 Results and 2021 Outlook GlobeNewswire Inc. - 1/7/2021 6:05:00 AM

Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 1/4/2021 6:05:00 AM

Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (N... GlobeNewswire Inc. - 12/14/2020 5:00:00 AM

Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA®... GlobeNewswire Inc. - 12/12/2020 9:30:00 PM

VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessio... GlobeNewswire Inc. - 12/7/2020 7:00:00 AM

Amarin Files Patent Infringement Lawsuit Against Hikma GlobeNewswire Inc. - 11/30/2020 7:54:44 PM

Amarin to Present at Piper Sandler’s 32nd Annual Healthcare Conference (Virtual) GlobeNewswire Inc. - 11/24/2020 6:05:00 AM

Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China GlobeNewswire Inc. - 11/19/2020 6:30:00 PM

MARINO	Monday, 10/01/18 11:31:57 PM
Re: ClayTrader post# 146788
Post # of 327111

Thanks Clay. Now we go down 5% tomorrow. But this time it's ok. I'm Short

Public Reply | Private Reply | Keep | Last Read

Next 10 | Previous | Next

Follow Board

Keyboard Shortcuts

Report TOS Violation

X


Current Price
Change
Volume
Detailed Quote - Discussion Board

+/- to Watchlist

Consent Preferences